

**Peptide Array, SARS Coronavirus Nucleocapsid (N) Protein**

**Catalog No. NR-52419**

This reagent is the tangible property of the U.S. Government.

**Product Description:**

The 57-peptide array spans the nucleocapsid (N) protein of the Urbani strain of severe acute respiratory syndrome coronavirus (SARS-CoV; GenPept: [AY278741](#)). Peptides are 15- to 20-mers, with 10 amino acid overlaps.

**Lot: U941XFC190**

The following information applies to all peptides:

- Appearance White lyophilized powder
- Mass spectral analysis Correct MW by MALDI or Electrospray
- Counter Ion Trifluoroacetate

Peptide-specific information is shown in the tables and figures below.

**Table 1: Peptide Analysis**

Peptide	Mfg. Date	Length	Sequence	Molecular Weight (amu)	Purity by HPLC <sup>1</sup>	Peptide Content <sup>2</sup>
1 of 57	4/19/2020	16	1-MSDNGPQSNQRSAPRI-16	1757.7	93.1%	71.01%
2 of 57	4/21/2020	18	7-QSNQRSAPRITFGGPTDS-24	1918.5	89.4%	84.66%
3 of 57	4/23/2020	19	15-RITFGGPTDSTDNNQNGGR-33	2006.4	85.8%	67.12%
4 of 57	4/21/2020	18	24-STDNNQNGGRNGARPKQR-41	1969.8	86.9%	76.53%
5 of 57	4/19/2020	15	32-GRNGARPKQRRPQGL-46	1690.8	99.2%	63.04%
6 of 57	4/18/2020	18	37-RPKQRRPQGLPNNTASWF-54	2152.8	87.0%	65.85%
7 of 57	6/10/2020	18	45-GLPNNTASWFTALTQHGK-62	1943.1	87.6%	80.88%
8 of 57	4/22/2020	17	53-WFTALTQHGKEELRFPR-69	2116.0	92.3%	56.28%
9 of 57	4/18/2020	16	60-HGKEELRFPRGQGVPI-75	1819.8	98.5%	58.55%
10 of 57	4/21/2020	20	66-RFPRGQGVPIINTNSGPDDQI-85	2168.1	88.8%	71.24%
11 of 57	5/1/2020	18	76-NTNSGPDDQIGYRRATR-93	2083.5	86.6%	73.27%
12 of 57	5/13/2020	18	84-QIGYRRATRRVRGGDGK-101	2109.0	95.1%	64.90%
13 of 57	5/1/2020	18	92-TRVRGGDGKMKELSPRW-109	2129.0	88.2%	72.41%
14 of 57	4/19/2020	15	100-GMKELSPRWYFYLL-114	1981.2	99.2%	56.40%
15 of 57	4/19/2020	18	105-LSPRWYFYLLGTGPEASL-122	2120.1	95.1%	53.85%
16 of 57	4/20/2020	16	113-YLGTGPEASLPYGANK-128	1637.2	97.8%	86.16%
17 of 57	4/19/2020	17	119-EASLPYGANKEGIVWVA-135	1803.6	95.7%	68.69%
18 of 57	4/24/2020	15	126-ANKEGIVWVATEGAL-140	1557.4	92.9%	82.80%
19 of 57	4/20/2020	17	131-IVWVATEGALNTPKDHI-147	1863.6	93.4%	84.44%
20 of 57	5/3/2020	19	138-GALNTPKDHIGTRNPNNA-156	2003.7	91.3%	63.68%
21 of 57	4/20/2020	16	147-IGTRNPNNAATVLQL-162	1695.4	89.6%	82.56%
22 of 57	5/15/2020	18	153-NNNAATVLQLPQGTTLPK-170	1879.6	93.5%	78.31%
23 of 57	4/23/2020	18	161-QLPQGTTLPKGFYAEGSR-178	1949.7	86.8%	50.51%
24 of 57	4/24/2020	18	169-PKGFYAEGSRGGSQASSR-186	1841.6	93.8%	78.76%
25 of 57	6/11/2020	16	177-SRGGSQASSRSSRSR-192	1652.4	96.5%	51.54%
26 of 57	4/22/2020	17	183-ASSRSSRSRGNSRNST-199	1796.4	88.0%	50.34%
27 of 57	4/15/2020	15	190-RSRGNSRNSTPGSSR-204	1618.4	96.6%	69.54%
28 of 57	4/29/2020	18	195-SRNSTPGSSRGNSPARMA-212	1832.4	89.0%	66.33%

Table 1: Peptide Analysis (continued)

Peptide	Mfg. Date	Length	Sequence	Molecular Weight (amu)	Purity by HPLC <sup>1</sup>	Peptide Content <sup>2</sup>
29 of 57	4/25/2020	18	203-SRGNSPARMASGGGETAL-220	1718.2	89.2%	70.45%
30 of 57	5/3/2020	18	211-MASGGGETALALLLLDRL-228	1800.6	85.0%	67.34%
31 of 57	5/3/2020	17	219-ALALLLLDRLNQLESKV-235	1908.8	97.6%	63.00%
32 of 57	4/26/2020	18	226-DRLNQLESKVSQKGGQQQ-243	2043.0	94.3%	72.86%
33 of 57	4/21/2020	17	234-KVSGKGGQQGQVTVTKK-250	1829.6	90.2%	75.88%
34 of 57	6/7/2020	18	241-QQQGQVTVTKKSAEASKK-258	1919.0	96.0%	52.32%
35 of 57	4/16/2020	17	249-KKSAAEASKKPRQKRTA-265	1884.8	93.9%	68.51%
36 of 57	4/16/2020	16	256-SKKPRQKRTATKQYNV-271	1932.8	97.5%	68.09%
37 of 57	4/26/2020	17	262-KRTATKQYNVTAQFGRR-278	2025.0	90.8%	67.82%
38 of 57	4/22/2020	19	269-YNVTQAFGRRGPEQTQGNF-287	2169.9	88.0%	65.37%
39 of 57	4/18/2020	17	278-RGPEQTQGNFGDQLIR-294	1930.4	92.7%	84.34%
40 of 57	4/19/2020	18	285-GNFGDQLIRQGTQDYKHW-302	2149.8	88.4%	65.13%
41 of 57	4/19/2020	17	293-IRQGTQDYKHWPQIAQFA-309	2058.9	97.0%	57.53%
42 of 57	4/20/2020	17	300-KHWPQIAQFAPSASAFF-316	1932.8	90.4%	84.65%
43 of 57	4/22/2020	17	307-QFAPSASAFFGMSRIGM-323	1804.6	88.0%	67.49%
44 of 57	4/24/2020	18	314-AFFGMSRIGMEVTPSGTW-331	1973.4	86.4%	78.54%
45 of 57	4/19/2020	18	322-GMEVTPSGTWLTYHGAIK-339	1947.8	92.3%	85.33%
46 of 57	4/19/2020	18	330-TWLTYHGAIKLDDKDPQF-347	2148.4	93.3%	74.30%
47 of 57	4/21/2020	17	338-IKLDDKDPQFKNVILL-354	2013.9	94.8%	73.37%
48 of 57	4/20/2020	18	345-PQFKDNVILLNKHIDAYK-362	2156.4	90.3%	63.68%
49 of 57	4/19/2020	18	353-LLNKHIDAYKTFPTEPK-370	2112.0	85.7%	63.81%
50 of 57	4/19/2020	16	361-YKTFPTEPKKDKKKK-376	1963.2	98.6%	51.05%
51 of 57	4/19/2020	17	367-TEPKKDKKKKTDEAQPL-383	1984.0	94.4%	53.47%
52 of 57	4/18/2020	16	374-KKKTDEAQPLPQRQKK-389	1922.8	96.4%	61.62%
53 of 57	4/19/2020	17	380-AQPLPQRQKKQPTVTLL-396	1946.1	95.4%	70.83%
54 of 57	4/24/2020	18	387-QKKQPTVTLLPAADMDDF-404	2017.8	85.1%	67.80%
55 of 57	4/21/2020	18	395-LLPAADMDDFSRQLQNSM-412	2052.0	86.3%	87.96%
56 of 57	4/19/2020	15	403-DFSRQLQNSMSGASA-417	1598.2	94.7%	65.27%
57 of 57	6/8/2020	15	408-LQNSMSGASADSTQA-422	1467.2	93.7%	82.39%

<sup>1</sup>Percent full length

<sup>2</sup>Remainder is salt and water

Figure 1: Amino Acid Analysis<sup>3</sup>

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
1 of 57	Expected	1.0	2.0	3.0		2.0	1.0		1.0			1.0		2.0	3.0				
	Actual	1.1	1.9	2.9		2.1	1.0		0.9			0.9		2.0	2.6				
2 of 57	Expected	1.0	2.0	2.0		2.0	2.0		1.0				1.0	2.0	3.0	2.0			
	Actual	1.1	1.9	2.0		2.1	2.1		0.8				1.0	2.1	2.7	1.7			
3 of 57	Expected		2.0	5.0		1.0	4.0		1.0				1.0	1.0	1.0	3.0			
	Actual		1.8	5.0		1.2	4.0		0.8				1.1	1.1	0.8	2.8			
4 of 57	Expected	1.0	3.0	5.0		2.0	3.0				1.0			1.0	1.0	1.0			
	Actual	1.1	3.0	4.8		2.2	3.0				1.0			1.0	0.8	0.8			
5 of 57	Expected	1.0	4.0	1.0		2.0	3.0			1.0	1.0			2.0					
	Actual	1.0	3.8	1.0		2.1	2.8			1.0	0.9			2.0					
6 of 57	Expected	1.0	3.0	2.0		2.0	1.0			1.0	1.0		1.0	3.0	1.0	1.0	1.0		
	Actual	1.1	2.7	2.0		2.1	1.0			0.9	0.9		0.9	2.9	0.9	0.9	0.0		
7 of 57	Expected	2.0		2.0		1.0	2.0	1.0		2.0	1.0		1.0	1.0	1.0	3.0	1.0		
	Actual	2.1		1.9		1.0	2.0	1.3		2.0	1.0		1.1	1.0	0.9	2.8	0.0		

Figure 1: Amino Acid Analysis (continued)<sup>3</sup>

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
8 of 57	Expected	1.0	2.0			3.0	1.0	1.0		2.0	1.0		2.0	1.0		2.0	1.0		
	Actual	1.1	1.9			3.1	1.0	0.9		1.9	0.9		1.9	1.0		1.7	0.0		
9 of 57	Expected		2.0			3.0	3.0	1.0	1.0	1.0	1.0		1.0	2.0					1.0
	Actual		1.9			3.1	3.0	1.1	1.0	1.0	1.0		1.0	2.0					1.0
10 of 57	Expected		2.0	4.0		2.0	3.0		2.0				1.0	3.0	1.0	1.0			1.0
	Actual		1.9	3.9		2.1	2.9		1.9				0.9	2.9	0.9	0.9			0.9
11 of 57	Expected	1.0	3.0	4.0		1.0	2.0		1.0					1.0	1.0	2.0		2.0	
	Actual	1.0	3.1	3.9		1.0	2.2		1.1					1.1	0.9	1.7		2.3	
12 of 57	Expected	1.0	5.0	1.0		1.0	4.0		1.0		1.0					1.0		2.0	1.0
	Actual	1.0	4.7	1.0		1.1	4.0		1.0		0.9					0.9		2.0	0.9
13 of 57	Expected		4.0	1.0		1.0	3.0			1.0	2.0	1.0		1.0	1.0	1.0	1.0		1.0
	Actual		3.7	1.0		1.1	3.0			1.0	1.9	1.0		1.0	0.9	0.9	0.0		1.1
14 of 57	Expected		1.0			1.0	1.0			2.0	2.0	1.0	1.0	1.0	1.0		1.0	3.0	
	Actual		1.0			1.1	1.0			2.0	2.0	1.0	1.0	1.0	0.9		0.0	2.9	
15 of 57	Expected	1.0	1.0			1.0	2.0			3.0			1.0	2.0	2.0	1.0	1.0	3.0	
	Actual	1.0	0.8			1.3	1.9			2.8			1.0	2.4	1.4	0.7	0.0	2.9	
16 of 57	Expected	2.0		1.0		1.0	3.0			2.0	1.0			2.0	1.0	1.0		2.0	
	Actual	2.0		1.0		1.1	2.9			1.9	1.0			2.0	0.9	0.9		1.9	
17 of 57	Expected	3.0		1.0		2.0	2.0		1.0	1.0	1.0			1.0	1.0		1.0	1.0	2.0
	Actual	3.0		1.0		2.2	2.0		0.9	1.0	0.9			1.1	0.9		0.0	1.1	1.4
18 of 57	Expected	3.0		1.0		2.0	2.0		1.0	1.0	1.0					1.0	1.0		2.0
	Actual	3.0		1.0		2.2	2.0		0.8	1.0	1.0					1.0	0.0		1.9
19 of 57	Expected	2.0		2.0		1.0	1.0	1.0	2.0	1.0	1.0			1.0		2.0	1.0		2.0
	Actual	2.1		2.1		1.2	1.0	0.9	1.6	1.0	1.0			1.0		1.9	0.0		1.5
20 of 57	Expected	2.0	1.0	6.0			2.0	1.0	1.0	1.0	1.0			2.0		2.0			
	Actual	1.9	1.0	6.0			2.1	1.0	1.2	1.0	0.9			2.1		1.7			
21 of 57	Expected	2.0	1.0	4.0		1.0	1.0		1.0	2.0				1.0		2.0			1.0
	Actual	2.1	1.0	3.9		1.1	0.9		0.9	2.0				1.0		1.6			0.8
22 of 57	Expected	2.0		3.0		2.0	1.0			3.0	1.0			2.0		3.0			1.0
	Actual	2.0		2.7		2.3	1.0			3.1	1.0			2.1		2.7			1.0
23 of 57	Expected	1.0	1.0			3.0	3.0			2.0	1.0		1.0	2.0	1.0	2.0		1.0	
	Actual	1.1	1.0			3.0	3.2			2.0	0.8		1.2	2.1	0.9	1.7		1.1	
24 of 57	Expected	2.0	2.0			2.0	4.0				1.0		1.0	1.0	4.0			1.0	
	Actual	1.9	2.1			1.9	4.0				1.0		1.0	1.0	3.8			1.0	
25 of 57	Expected	1.0	4.0			1.0	2.0								8.0				
	Actual	0.9	3.4			1.1	1.8								5.5				
26 of 57	Expected	1.0	4.0	2.0			1.0								8.0	1.0			
	Actual	1.1	3.7	1.9			1.0								6.4	0.8			
27 of 57	Expected		4.0	2.0			2.0							1.0	5.0	1.0			
	Actual		4.0	2.0			2.0							1.0	4.6	0.9			
28 of 57	Expected	2.0	3.0	2.0			2.0					1.0		2.0	5.0	1.0			
	Actual	1.9	2.9	2.1			2.0					1.0		1.9	4.5	0.9			
29 of 57	Expected	3.0	2.0	1.0		1.0	4.0			1.0				1.0	3.0	1.0			
	Actual	2.9	1.9	1.0		1.1	3.9			1.0				1.0	2.6	0.9			
30 of 57	Expected	3.0	1.0	1.0		1.0	3.0			6.0		1.0			1.0	1.0			
	Actual	2.9	1.0	1.0		1.1	2.9			6.0		0.9			0.9	0.9			
31 of 57	Expected	2.0	1.0	2.0		2.0				7.0	1.0				1.0				1.0
	Actual	2.0	1.0	1.9		2.1				6.9	1.0				0.9				1.0
32 of 57	Expected		1.0	2.0		6.0	2.0			2.0	2.0				2.0				1.0
	Actual		1.0	1.9		6.2	2.2			2.1	1.8				1.7				1.0
33 of 57	Expected					5.0	3.0				4.0				1.0	2.0			2.0
	Actual					5.3	2.9				3.7				0.9	1.6			1.7
34 of 57	Expected	3.0				5.0	1.0				4.0				2.0	2.0			1.0
	Actual	3.1				5.3	1.0				3.6				1.9	1.8			0.9
35 of 57	Expected	4.0	2.0			2.0					5.0			1.0	2.0	1.0			
	Actual	4.0	2.1			2.2					4.7			1.0	1.8	1.0			
36 of 57	Expected	1.0	2.0	1.0		2.0					4.0			1.0	1.0	2.0		1.0	1.0
	Actual	1.1	2.0	1.0		2.2					3.7			1.1	0.9	1.8		1.1	1.1

Figure 1: Amino Acid Analysis (continued)<sup>3</sup>

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
37 of 57	Expected	2.0	3.0	1.0		2.0	1.0				2.0		1.0			3.0		1.0	1.0
	Actual	1.9	2.8	1.0		2.2	1.0				1.8		1.0			2.7		1.0	1.0
38 of 57	Expected	1.0	2.0	2.0		4.0	3.0						2.0	1.0		2.0		1.0	1.0
	Actual	1.1	1.9	1.9		4.0	2.7						2.0	0.9		1.6		1.0	0.9
39 of 57	Expected		2.0	3.0		4.0	3.0		1.0	1.0			1.0	1.0		1.0			
	Actual		1.7	3.0		4.2	3.0		0.8	0.9			1.0	1.0		0.9			
40 of 57	Expected		1.0	4.0		2.0	3.0	1.0	1.0	1.0	1.0		1.0			1.0	1.0	1.0	
	Actual		0.8	4.1		2.3	3.0	1.1	0.7	0.9	1.0		1.0			1.0	0.0	1.1	
41 of 57	Expected	2.0	1.0	1.0		3.0	1.0	1.0	2.0		1.0		1.0	1.0		1.0	1.0	1.0	
	Actual	2.1	0.9	1.0		3.3	1.0	1.1	1.7		0.9		1.0	1.0		0.9	0.0	1.0	
42 of 57	Expected	4.0				2.0		1.0	1.0		1.0		3.0	2.0	2.0		1.0		
	Actual	4.0				2.2		0.9	1.0		0.9		3.2	2.1	1.9		0.0		
43 of 57	Expected	3.0	1.0			1.0	2.0		1.0			2.0	3.0	1.0	3.0				
	Actual	3.0	1.0			1.1	2.0		0.9			2.0	3.0	1.0	2.7				
44 of 57	Expected	1.0	1.0			1.0	3.0		1.0			2.0	2.0	1.0	2.0	2.0	1.0		1.0
	Actual	1.1	0.9			1.0	2.7		0.9			1.7	1.7	0.9	1.7	1.7	0.0		0.9
45 of 57	Expected	1.0				1.0	3.0	1.0	1.0	1.0	1.0	1.0		1.0	1.0	3.0	1.0	1.0	1.0
	Actual	1.1				1.1	3.0	1.0	0.9	1.0	0.9	1.0		1.0	0.9	2.8	0.0	1.0	1.0
46 of 57	Expected	1.0		3.0		1.0	1.0	1.0	1.0	2.0	2.0		1.0	1.0		2.0	1.0	1.0	
	Actual	1.1		3.2		1.1	1.1	1.1	0.8	2.1	1.7		1.1	1.1		1.9	0.0	1.1	
47 of 57	Expected			5.0		1.0			2.0	3.0	3.0		1.0	1.0					1.0
	Actual			5.3		1.2			1.7	3.2	2.7		1.1	1.1					0.9
48 of 57	Expected	1.0		4.0		1.0		1.0	2.0	2.0	3.0		1.0	1.0				1.0	1.0
	Actual	1.1		4.1		1.1		0.9	1.7	2.0	2.9		1.0	1.0				1.0	0.7
49 of 57	Expected	1.0		2.0		1.0		1.0	1.0	2.0	3.0		1.0	3.0		2.0		1.0	
	Actual	1.2		1.9		1.1		1.0	0.9	2.0	2.9		1.1	3.3		1.7		1.1	
50 of 57	Expected			1.0		1.0					7.0		1.0	3.0		2.0		1.0	
	Actual			1.1		1.2					6.8		1.1	3.4		1.9		1.1	
51 of 57	Expected	1.0		2.0		3.0				1.0	6.0			2.0		2.0			
	Actual	1.1		2.1		3.2				1.0	5.6			2.0		1.8			
52 of 57	Expected	1.0	1.0	1.0		4.0				1.0	5.0			2.0		1.0			
	Actual	1.1	1.0	1.0		4.4				1.0	4.5			2.0		0.9			
53 of 57	Expected	1.0	1.0			4.0				3.0	2.0			3.0		2.0			1.0
	Actual	1.0	1.0			4.2				3.0	1.8			3.0		1.6			0.9
54 of 57	Expected	2.0		3.0		2.0				2.0	2.0	1.0	1.0	2.0		2.0			1.0
	Actual	2.1		3.0		2.1				2.0	1.9	1.0	1.1	2.2		1.6			0.9
55 of 57	Expected	2.0	1.0	4.0		2.0				3.0		2.0	1.0	1.0	2.0				
	Actual	2.0	1.0	3.9		2.2				2.9		2.0	1.0	1.0	1.7				
56 of 57	Expected	2.0	1.0	2.0		2.0	1.0			1.0		1.0	1.0		4.0				
	Actual	2.0	1.0	1.9		2.1	1.0			1.0		1.0	1.0		3.5				
57 of 57	Expected	3.0		2.0		2.0	1.0			1.0		1.0			4.0	1.0			
	Actual	3.0		1.8		1.9	1.2			1.3		1.2			3.2	0.8			

<sup>3</sup>Tryptophan (W) was completely destroyed during hydrolysis. Serine (S) and threonine (T) were partially destroyed during hydrolysis.

Table 2: Peptide Solubility<sup>4</sup>

Peptide	Sequence	Water Solubility, mg/mL	DPBS Solubility, mg/mL	DMSO Solubility, mg/mL
1 of 57	1-MSDNGPQSNQRSAPRI-16	5	5	5
2 of 57	7-QSNQRSAPRITFGGPTDS-24	N/A	N/A	10
3 of 57	15-RITFGGPTDSTDNNQNGGR-33	N/A	N/A	10
4 of 57	24-STDNNQNGGRNGARPKQR-41	5	5	10
5 of 57	32-GRNGARPKQRRPQGL-46	10	10	10
6 of 57	37-RPKQRRPQGLPNTASWF-54	5	5	10

Table 2: Peptide Solubility (continued)<sup>4</sup>

Peptide	Sequence	Water Solubility, mg/mL	DPBS Solubility, mg/mL	DMSO Solubility, mg/mL
7 of 57	45-GLPNNTASWFTALTQHGK-62	N/A	2	5
8 of 57	53-WFTALTQHGKEELRFPR-69	5	5	10
9 of 57	60-HGKEELRFPRGQGVPI-75	N/A	2	10
10 of 57	66-RFPRGQGVPIINTNSGPDDQI-85	5	5	10
11 of 57	76-NTNSGPDDQIGYYRRATR-93	5	5	10
12 of 57	84-QIGYYRRATRRVRGGDGK-101	5	5	10
13 of 57	92-TRRVRGGDGKMKELSPRW-109	5	5	10
14 of 57	100-GKMKELSPRWYFYLL-114	N/A	N/A	10
15 of 57	105-LSPRWYFYLLGTGPEASL-122	N/A	N/A	10
16 of 57	113-YLGTGPEASLPYGANK-128	10	10	10
17 of 57	119-EASLPYGANKEGIVWVA-135	5	5	10
18 of 57	126-ANKEGIVWVATEGAL-140	5	5	10
19 of 57	131-IVWVATEGALNTPKDHI-147	5	5	10
20 of 57	138-GALNTPKDHIGTRNPNNNA-156	5	5	10
21 of 57	147-IGTRNPNNNAATVLQL-162	5	5	5
22 of 57	153-NNNAATVLQLPQGTTLPK-170	5	N/A	10
23 of 57	161-QLPQGTTLPKGFYAEGSR-178	5	5	5
24 of 57	169-PKGFYAEGSRGGSQASSR-186	5	5	10
25 of 57	177-SRGGSQASSRSSSRSR-192	5	5	5
26 of 57	183-ASSRSSSRSRGNSRNST-199	10	5	10
27 of 57	190-RSRGNSRNSTPGSSR-204	5	5	5
28 of 57	195-SRNSTPGSSRGNSPARMA-212	5	5	10
29 of 57	203-SRGNSPARMASGGGETAL-220	10	10	15
30 of 57	211-MASGGGETALALLLDRL-228	N/A	N/A	10
31 of 57	219-ALALLLDRLNQLESKV-235	5	N/A	5
32 of 57	226-DRLNQLESKVSQGGQQQ-243	5	2	5
33 of 57	234-KVSGKQQQQGQTVTKK-250	5	5	10
34 of 57	241-QQQGQTVTKKSAEASKK-258	5	5	5
35 of 57	249-KKSAEASKKPRQRKA-265	5	5	10
36 of 57	256-SKKPRQKRTATKQYNV-271	5	5	10
37 of 57	262-KRTATKQYNVTQAFGRR-278	5	5	5
38 of 57	269-YNVTQAFGRRGPEQTQGNF-287	N/A	N/A	5
39 of 57	278-RGPEQTQGNFGDQDLIR-294	N/A	N/A	10
40 of 57	285-GNFGDQDLIRQGTDYKHW-302	10	10	10
41 of 57	293-IRQGTDYKHWPIAQFA-309	10	10	10
42 of 57	300-KHWPQIAQFAPSASAFF-316	2	N/A	10
43 of 57	307-QFAPSASAFFGMSRIGM-323	N/A	N/A	10
44 of 57	314-AFFGMSRIGMEVTPSGTW-331	N/A	N/A	10
45 of 57	322-GMEVTPSGTWLTYHGAIK-339	5	5	5

Table 2: Peptide Solubility (continued)<sup>4</sup>

Peptide	Sequence	Water Solubility, mg/mL	DPBS Solubility, mg/mL	DMSO Solubility, mg/mL
46 of 57	330-TWLTYHGAIKLDDKDPQF-347	N/A	N/A	10
47 of 57	338-IKLDDKDPQFKDNVILL-354	5	5	10
48 of 57	345-PQFKDNVILLNKHIDAYK-362	5	5	5
49 of 57	353-LLNKHIDAYKTFPTEPK-370	10	10	10
50 of 57	361-YKTFPTEPKDKKKK-376	10	10	10
51 of 57	367-TEPKDKKKKTDEAQPL-383	10	10	10
52 of 57	374-KKKTDEAQPLPQRQKK-389	10	10	10
53 of 57	380-AQPLPQRQKKQPTVTLL-396	10	10	10
54 of 57	387-QKKQPTVTLLPAADMDDF-404	5	5	10
55 of 57	395-LLPAADMDDFSRQLQNSM-412	5	5	10
56 of 57	403-DFSRQLQNSMSGASA-417	10	10	10
57 of 57	408-LQNSMSGASADSTQA-422	N/A <sup>5</sup>	N/A <sup>5</sup>	N/A <sup>5</sup>

<sup>4</sup>N/A signifies solubility less than 0.1 mg/mL.

<sup>5</sup>Peptide 57 was soluble in 3% ammonia in water at 2 mg/mL.

/Heather Couch/  
Heather Couch

21 AUG 2020

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by the vendor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

